|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-4-19
|
|
pubmed:abstractText |
Primary systemic therapy (PST) with gemcitabine (G), epirubicin (E), and docetaxel (Doc) has resulted in a pathologic complete response (pCR) in 26% of primary breast cancer patients. This study was aimed at the identification of a gene expression signature in diagnostic core biopsy tissue samples that predicts pCR.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BennerAxelA,
pubmed-author:BrorsBenediktB,
pubmed-author:EilsRolandR,
pubmed-author:HahnMeinhardM,
pubmed-author:KramerHeidiH,
pubmed-author:LichterPeterP,
pubmed-author:RudlowskiChristianC,
pubmed-author:SchneeweissAndreasA,
pubmed-author:SchuetzFlorianF,
pubmed-author:SinnHans-PeterHP,
pubmed-author:SohnChristofC,
pubmed-author:TewsBjoernB,
pubmed-author:ThuerigenOlafO,
pubmed-author:ToedtGrischaG,
pubmed-author:WarnatPatrickP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1839-45
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16622258-Adult,
pubmed-meshheading:16622258-Aged,
pubmed-meshheading:16622258-Algorithms,
pubmed-meshheading:16622258-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16622258-Breast Neoplasms,
pubmed-meshheading:16622258-Deoxycytidine,
pubmed-meshheading:16622258-Epirubicin,
pubmed-meshheading:16622258-Female,
pubmed-meshheading:16622258-Gene Expression Profiling,
pubmed-meshheading:16622258-Humans,
pubmed-meshheading:16622258-Immunohistochemistry,
pubmed-meshheading:16622258-Middle Aged,
pubmed-meshheading:16622258-Multivariate Analysis,
pubmed-meshheading:16622258-Predictive Value of Tests,
pubmed-meshheading:16622258-Sensitivity and Specificity,
pubmed-meshheading:16622258-Taxoids,
pubmed-meshheading:16622258-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
|
|
pubmed:affiliation |
Division of Molecular Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
